Alliance Pharma Regulatory News (APH)

12 May 2006 10:19

Alliance Pharma PLC12 May 2006 For immediate release 12 May 2006 ALLIANCE PHARMA PLC ("Alliance" or "the Company") AGM Statement Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,held its Annual General Meeting earlier today at which all resolutions were dulypassed. Michael Gatenby, the Company's Chairman, made the following comments: "I ampleased to report that trading for the year to date is in line with managementexpectations. We are benefiting from the recent acquisition of the Hydromolrange of dermatology products and we continue to look for further appropriateopportunities to bring additional products into our portfolio. "Our pipeline products are moving closer to regulatory submission. Phase IIIclinical trials are on-going and, as part of our pre-marketing activities, wecontinue to work closely with leading clinicians and recently held a successfulsymposium on the use of melatonin for sleep disorders held last month at theRoyal Society of Medicine in London." For further information: Alliance Pharma plc + 44 (0)1249 466 966 John Dawson, Chief Executive Maddy Scott, Finance Director www.alliancepharma.co.uk Buchanan Communications + 44 (0)20 7466 5000 Mark Court/Lisa Baderoon/Rebecca Skye Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 30 branded pharmaceutical products and continues to exploreopportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to UK and International pharmaceuticalwholesalers which service both hospital and retail pharmacies with theirprescription requirements. Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor forthe induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange